Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?

Journal article

In the past ten years, primary percutaneous coronary intervention (PCI) has replaced thrombolysis as the revascularisation strategy for many patients presenting with ST-segment elevation myocardial infarction (STEMI). However, delivery of primary PCI within evidence-based timeframes is challenging, and health-care provision varies substantially worldwide. Consequently, even with the ideal circumstances of rapid initial diagnosis, long transfer delays to the catheter laboratory can occur. These delays are detrimental to outcomes for patients and can be exaggerated by variations in timing of patients' presentation and diagnosis. In this Series paper we summarise the value of immediate out-of-hospital thrombolysis for STEMI, and reconsider the potential therapeutic interface with a contemporary service for primary PCI. We review recent trial data, and explore opportunities for optimisation of STEMI outcomes with a pharmacoinvasive approach.

Authors: Gershlick, A; Banning, A; Myat, A; Verheugt, F; Gersh, B

• Journal: Lancet
• Volume: 382
• Issue: 9892
• Pages: 624-632
• Publication date: 2013-08-01
• DOI: 10.1016/s0140-6736(13)61454-3
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Time Factors; Fibrinolytic Agents; Humans; Combined Modality Therapy; Thrombolytic Therapy; Percutaneous Coronary Intervention; Myocardial Infarction; Myocardial Reperfusion